This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
News

Two new therapies for type 2 diabetes approved for use by NHS Scotland

The Scottish Medicines Consortium (SMC) recently published advice pertaining to the acceptance of 2 new antidiabetic therapies for use by NHS Scotland.

Semaglutide (Ozempic) has been accepted for treating inadequately controlled type 2 diabetes (T2D) in adults as an adjunct to diet and exercise. It may be added to the existing regimen of other anti-diabetic medications, as an add-on to basal insulin or as an alternative to another glucagon-like peptide-1 receptor agonist. It is not recommended by SMC as monotherapy when metformin cannot be used due to intolerance or contraindications. Randomised comparative studies showed semaglutide once weekly to be superior to comparators for change in HbA1c.

Ertugliflozin (Steglatro) has been accepted for treating T2D in adults as an adjunct to diet and exercise. It may be used as add-on therapy to the current anti-diabetic drug regimen. It may also be given as monotherapy to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and are deemed unsuitable for receiving sulphonylurea or pioglitazone. Phase 3 studies in mono, dual and triple therapy settings demonstrated superiority of ertugliflozin over placebo in lowering HbA1c.


References


YOU MAY ALSO LIKE